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ABSTRACT
Objectives To develop and validate a specific protocol 
for SARS- CoV-2 detection in breast milk matrix and to 
determine the impact of maternal SARS- CoV-2 infection 
on the presence, concentration and persistence of 
specific SARS- CoV-2 antibodies.
Design and patients This is a prospective, multicentre 
longitudinal study (April–December 2020) in 60 mothers 
with SARS- CoV-2 infection and/or who have recovered 
from COVID-19. A control group of 13 women before the 
pandemic were also included.
Setting Seven health centres from different provinces 
in Spain.
Main outcome measures Presence of SARS- CoV-2 
RNA in breast milk, targeting the N1 region of the 
nucleocapsid gene and the envelope (E) gene; presence 
and levels of SARS- CoV-2- specific immunoglobulins 
(Igs)—IgA, IgG and IgM—in breast milk samples from 
patients with COVID-19.
Results All breast milk samples showed negative 
results for presence of SARS- CoV-2 RNA. We observed 
high intraindividual and interindividual variability in 
the antibody response to the receptor- binding domain 
of the SARS- CoV-2 spike protein for each of the three 
isotypes IgA, IgM and IgG. Main Protease (MPro) 
domain antibodies were also detected in milk. 82.9% 
(58 of 70) of milk samples were positive for at least 
one of the three antibody isotypes, with 52.9% of these 
positive for all three Igs. Positivity rate for IgA was 
relatively stable over time (65.2%–87.5%), whereas 
it raised continuously for IgG (from 47.8% for the first 
10 days to 87.5% from day 41 up to day 206 post- PCR 
confirmation).
Conclusions Our study confirms the safety of breast 
feeding and highlights the relevance of virus- specific 
SARS- CoV-2 antibody transfer. This study provides crucial 
data to support official breastfeeding recommendations 
based on scientific evidence.
Trial registration number NCT04768244.
INTRODUCTION
Breast feeding is considered the gold standard for 
infant feeding and is of crucial importance in influ-
encing both infant growth and development. Epide-
miological studies have demonstrated that breast 
feeding decreases risk of infections in infants.1–4 
Due to its beneficial effects, international organi-
sations including the WHO recommend exclusive 
breast feeding for the first 6 months of life, and 
continuing breast feeding while complementary 
foods are introduced until 2 years of age or beyond.5
The COVID-19 global pandemic caused by 
SARS- CoV-2 has increased concerns about poten-
tial mother- to- infant transmission, including via 
breast feeding. While some studies reported the 
presence of SARS- CoV-2 in breast milk,6 7 although 
its potential for infection is unclear,8 other studies 
found no presence of the virus.9–11 In general, 
these studies showed several limitations, with the 
most relevant being the lack of targeted and vali-
dated protocols for viral detection in milk matrix. 
Furthermore, a strong antibody response is induced 
after maternal SARS- CoV-2 infection, with higher 
presence of neutralising secretory IgA in breast 
milk.7 12 13 However, several questions remain unan-
swered, including a specific and reliable method to 
detect SARS- CoV-2 in human milk, the extent of 
What is already known on this topic?
 ► Breast feeding provides optimal nutrition in 
infants.
 ► Data are conflicting on whether SARS- CoV-2 is 
present in breast milk of infected mothers.
 ► Breast milk of infected mothers contains 
antibodies to SARS- CoV-2, especially IgA.
What this study adds?
 ► SARS- CoV-2 RNA was not detected in any of the 
breast milk samples from our study.
 ► There is high intra- and inter- individual 
variability in the antibody response against the 
receptor- binding domain of the SARS- CoV-2 
spike protein for the three antibody isotypes 
(IgA, IgM and IgG) and also against non- 
structural proteins, like MainProtease (MPro).
 ► Most of the breast milk samples (82.9%) had 
antibodies after SARS- CoV-2 infection for at 
least one of the three isotypes, with 52.9% of 
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the response, the persistence of maternal antibodies in milk and 
their potential protective role in infants. Under this scenario, our 
main objectives were (1) to provide a specific and reliable detec-
tion method for SARS- CoV-2 in breast milk; and (2) to deter-
mine the levels of reactive IgA, IgG and IgM antibodies against 
structural and non- structural SARS- CoV-2 proteins in breast 
milk collected during the COVID-19 pandemic.
MATERIALS AND METHODS
Study population
This is a prospective, observational, longitudinal and multicentre 
study in mother–infant pairs with confirmed SARS- CoV-2 infec-
tion. Participants were recruited from seven health centres from 
different provinces in Spain (Valencia, Barcelona, Granada and 
Zaragoza). The recruitment period was from April to December 
2020. Participants were pregnant women intending to breast 
feed and nursing women with positive PCR for SARS- CoV-2 on 
nasopharyngeal swabs or presence of SARS- CoV-2 antibodies 
in serum determined in hospitals. Women were excluded when 
COVID-19 symptomatology required specific treatment and/or 
hospitalisation in intensive care units. Exclusion criteria included 
women unable to breast feed due to severe symptomatology that 
required intensive care unit and/or mother’s need for drugs 
with potential adverse effects on the infant and/or impossi-
bility to obtain milk. All participants received oral and written 
information about the study and written consent was obtained. 
Extended details on the control group are described in online 
supplemental text S1.
Breast milk collection and processing
Breast milk was collected following a standardised protocol 
described elsewhere.14 Details on collection, sampling and 
storage are described in online supplemental text S1. Whole milk 
was used for SARS- CoV-2 RNA detection and whey milk was 
used for antibody determination. Further details are provided in 
online supplemental text S1.
Validation of SARS-CoV-2 RNA extraction, detection and 
quantification in breast milk samples
A manual column- based commercial kit (referred to as MN) and 
an automated assisted method based on magnetic beads (referred 
to as Max) were adapted following previous recommendations15 
and were compared to assess their sensitivity in detecting viral 
particles in breast milk. Details related to RNA extraction proce-
dures, viral recoveries with different virus and limits of detection 
(LoD95% and LoD50%) are provided in online supplemental text 
S1.
Breast milk SARS-CoV-2-specific antibody detection
Levels of antibodies directed to structural (receptor- binding 
domain (RBD) of the SARS- CoV-2 spike protein) and non- 
structural (the main protease MPro or 3C- like protease 
(3CLpro)) viral proteins were analysed (online supplemental 
text S1). RBD- specific antibodies were determined by ELISA as 
previously described.16 17 MPro- reactive antibodies were quan-




Maternal demographic and clinical characteristics of women 
from the COVID-19 pandemic period group (n=60) and the 
prepandemic group (n=13) are described in table 1. Among the 
60 mothers, 52 were diagnosed with SARS- CoV-2 PCR test on 
nasopharyngeal swabs while 8 were seropositive (IgG- positive). 
Most PCR tests (38 of 52, 73.1%) were performed as part of 
routine surveillance before labour (online supplemental text S2, 
Table 1 Characteristics of the volunteers included in the study
COVID-19 (n=60) Prepandemic control (n=13) P value
Maternal characteristics
Age 34.8±4.6* 33.8±4.2 0.483†
Gestational age (weeks)‡ 39.2 (38.1–40.6)§ 39 (39.0–40.0) 0.963†
Delivery mode, n (%)¶ 0.306**
  Vaginal 42 (76.4) 8 (61.5)
  Caesarean section 13 (23.6) 5 (38.5)
Infant characteristics
Birth weight (g) 3247±519†† 3323±475.7 0.630†
Birth length (cm) 49.8±2.4‡‡ 50.5±1.6 0.296†
Breastfeeding status§§, n (%) 0.756**
  Exclusive 35 (66.0) 8 (61.5)
  Mixed feeding 18 (34.0) 5 (38.5)
Gender¶¶, n (%) 0.533**
  Male 24 (44.4) 4 (30.8)
  Female 30 (55.6) 9 (69.2)
*Missing data from 4 individuals.
†Unpaired t- test.
‡Values are given as median and 25th and 75th percentile.
§Missing data from 10 individuals.
¶Missing data from 5 individuals.
**Fisher’s exact test (two- sided).
††Missing data from 8 individuals.
‡‡Missing data from 14 individuals.
§§Missing data from 7 individuals.
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table S1). Longitudinal samples from 12 women were available 
(two time points at <7 days and 15 days after delivery, approx-
imately). Of the women, 38 (63.3%) were asymptomatic, and 
the rest reported mild COVID-19 symptoms (pain, fatigue or 
headache, among others). No other effects or medical problems 
were reported. All neonates were negative for SARS- CoV-2 and 
in good health.
Validation of SARS-CoV-2 RNA extraction and detection 
methods in breast milk
Breast milk SARS- CoV-2 viral RNA detection was optimised with 
Porcine Epidemic Diarrhoea Virus (PEDV) strain CV777 and 
Mengovirus (MgV) vMC0 strain recoveries, and limits of detec-
tion (LoD95% and LoD50%) from spiked prepandemic breast milk 
samples using manual (MN) and an automated (Max) extraction 
method were tested (online supplemental text S2). These results 
suggested comparable analytical performance of both extraction 
methods for enveloped viruses; thus, the Max extraction method 
was further characterised using gamma inactivated SARS- CoV-2 
and human coronavirus (HCoV) 229E (ATCC- VR740) (online 
supplemental figure S1), along with PEDV and MgV, as the 
method intended to be used for screening breast milk samples 
from women with COVID-19. LoD95% values were as low as 36 
gc/100 µL, 209 gc/100 µL, 13 gc/100 µL and 7 gc/100 µL, and 
LoD50% values were 8 gc/100 µL, 48 gc/100 µL, 3 gc/100 µL 
and 2 gc/100 µL, for SARS- CoV-2, HCoV 229- E, PEDV and 
MgV, respectively (online supplemental figure S2). Based on 
these analytical results, the Max method was selected to screen 
the 72 breast milk samples for presence of SARS- CoV-2 RNA. 
Targeting the N1 and E regions, all samples resulted negative 
for presence of SARS- CoV-2 RNA. The RP gene used as quality 
control excluded false negative results (Cq=27.98±3.04). No 
remaining volume was available from 2 out of the 72 samples for 
the following analyses.
SARS-CoV-2 reactive antibodies in breast milk
We tested the reactivity of breast milk IgA, IgM and IgG anti-
bodies to the RBD of the spike glycoprotein. Prepandemic milk 
samples (n=13) served as controls and to determine positive cut- 
off values (online supplemental figure S3). Strong reactivity was 
found for IgA, IgM and IgG in milk samples from COVID-19 
infected/recovered women, and low levels of non- specific binding 
were observed in the prepandemic samples (online supplemental 
figure S4a- c). When applying positive cut- off levels, 84.5% (49 
of 58) of the milk samples were positive for the RBD antigen for 
at least one of the three antibody classes (online supplemental 
figure S4d). When analysing the 70 collected samples, 58 (82.9%) 
were positive at least for one of the three antibody classes (IgA, 
IgM or IgG). Thirty- seven milk samples (52.9%) were positive 
for all three immunoglobulins (Igs), whereas 12 samples (17.1%) 
did not show reactivity to RBD for any of the three antibody 
classes (online supplemental figure S4e). We corroborated our 
results using the MPro antigen.18 Milk samples from COVID-19 
infected and recovered donors still showed significantly higher 
reactivity to the MPro antigen than the prepandemic samples 
(online supplemental figure S5). Noteworthy, the positivity rate 
using this antigen decreased from 67.6% to 42.3% for IgA and 
from 64.2% to 31.3% for IgG.
Antibody response was analysed as a function of time from 
diagnosis with PCR test (online supplemental figure S6). The 
positivity rate for IgA was relatively stable over time (65.2%–
87.5%). Most positive samples for IgM were detected when 
collected at 11–20 days after PCR confirmation (83.3%), and 
then the levels consistently declined to 62.5%. IgG positivity 
rate continuously raised from 47.8% to 87.5% from day 41 up 
to day 206 post- PCR confirmation. RBD- specific IgA response 
in symptomatic COVID-19 cases tended to be higher than in the 
asymptomatic group, although differences did not reach signif-
icance and no changes were detected in virus- specific IgM and 
IgG (online supplemental figure S7).
We compared endpoint titres of positive samples between the 
different antibody isotypes and observed that the magnitude of 
the response was similar for all three Igs (online supplemental 
figure S8). Furthermore, all three Igs significantly correlated with 
each other, particularly IgA and IgM (r=0.7812, p<0.0001), 
but also IgA and IgG (r=0.6100, p<0.0001) and IgG and IgM 
(r=0.5708, p=0.0001).
A positive correlation (r=0.5527, p=0.0001) was also observed 
between the total IgA levels and the SARS- CoV-2- specific anti-
body response (online supplemental figure S9a). In fact, the total 
IgA levels were significantly higher in the COVID-19 group 
compared with the prepandemic controls (online supplemental 
figure S9b) and could be part of the response to infection. In a 
subset of longitudinal milk samples collected within the first 20 
days after birth, we observed a generalised decrease in IgA and 
endpoint titres for RBD except in one mother, which exhibited 
low but rising antibody titres in breast milk (online supplemental 
figure S10). Generally, total IgA concentrations correlated 
negatively with lactation stage (r=−0.3357, p=0.0045), 
similar to RBD- specific IgA (r=−0.3088, p=0.0093) and IgM 
(r=−0.4334, p=0.0002), while the RBD- specific IgG response 
was independent of lactation stage. Furthermore, there was 
high interindividual and intraindividual variability in the anti-
body response to the virus for each of the three isotypes (online 
supplemental figure S11). In most of the samples, lactation stage 
and post- PCR detection coincided in a narrow time period; in 
fact, for 40 of the positive tested samples in online supplemental 
figure S11a, the difference between PCR detection and birth was 
not more than 5 days. Seven out of the eight milk samples from 
seropositive women showed positive antibody responses for all 
three antibody classes, except one sample that tested negative for 
IgM (online supplemental figure S11b). The remaining sample 
tested negative for all three isotypes and was from a mother 
diagnosed with SARS- CoV-2 infection by serological testing 226 
days prior to sample collection for our study.
DISCUSSION
During the current COVID-19 pandemic, science has primarily 
focused on providing solutions and treatments against SARS- CoV-2 
infection to reduce mortality. However, specific vulnerable popu-
lations including pregnant and lactating mothers as well as infants 
have not been widely considered, resulting in a big gap in knowl-
edge on maternal- infant health regarding COVID-19.
Breast feeding is considered the most relevant postnatal link 
between mothers and infants. However, the lack of understanding 
of SARS- CoV-2 vertical transmission19 has considerably reduced 
breastfeeding practice. Even mothers with SARS- CoV-2 infection 
were recommended to temporarily separate from their infants.20
Being a rapid and sensitive technique, RNA detection by 
reverse transcription quantitative PCR (RT- qPCR) is the gold 
standard for both clinical diagnosis and viral food contamina-
tion.21 22 However, milk components might affect nucleic acid 
isolation and quantification, as demonstrated by the variable 
recovery of contaminating microorganisms and the occurrence 
of (partial/total) inhibitory effect during amplification, which 
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have also observed. Thus, it is of primary importance to include 
appropriate quality controls for extraction, detection and quan-
tification of molecular targets while defining the analytical 
performance of the overall workflow.26 In our study, whole milk 
was used to test for viral RNA presence. LoD95% and LoD50% for 
gamma inactivated SARS- CoV-2 resulted in values as low as 36 
gc/100 µL and 8 gc/100 µL, respectively. These data are in line 
with the detection limit suggested by Chambers and colleagues,27 
where samples with >25 gc/100 µL of SARS- CoV-2 RNA would 
be considered positive although a higher limit of ca. 103–4 
gc/100 μL was informed elsewhere.6
Available data show that around 2%–6% of milk samples 
would harbour viral RNA. A recent systematic review (n=37 
articles with 68 lactating mothers with COVID-19) showed 
that SARS- CoV-2 RNA was detected in nine of the samples 
(9 of 68, 13.2%).28 Another systematic review reported that 
SARS- CoV-2 RNA detection in breast milk was 2.16%.29 
The biggest study to date included 110 women in the USA 
(n=65 testing positive for SARS- CoV-2) and showed that 
SARS- CoV-2 RNA was present in 6% of the milk samples; 
however, no infectious viral particles could be isolated by cell 
culture.8 By using SARS- CoV-2, SARS- CoV-2 surrogates and 
a non- enveloped viral model (MgV), we define the analytical 
performance (eg, recovery and LoD) of a specific protocol 
able to efficiently isolate and detect SARS- CoV-2 RNA in 
breast milk. We further validate the protocol using appro-
priate quality controls in whole breast milk.
In our study, we have not detected SARS- CoV-2 RNA in 
any of the breast milk samples, contributing to the evidence 
that there is no vertical transmission during breast feeding.9 
There are still many open questions: when are SARS- CoV-2 
antibodies produced after maternal infection, when can they 
be detected in breast milk, and how long do they persist? 
While different studies reported the presence of SARS- CoV-
2- specific IgA antibodies,7 12 13 30 limited information is avail-
able on IgG and IgM. Our results showed the presence of 
anti- SARS- CoV-2 antibodies in milk, primarily IgA but also 
IgG and IgM targeting RBD. High intraindividual and inter-
individual variability was observed in antibody presence, 
and significant differences for all three antibody classes were 
identified when compared with the prepandemic samples.18 
We did not detect time- dependent quantitative differences in 
endpoint titres for the different antibody classes, most likely 
due to high interindividual variability. However, we found 
a time- dependent increase in IgG- positive samples collected 
from day 41 up to day 206 post- PCR diagnosis. These data are 
in line with findings in human serum samples from a Chinese 
cohort showing persistence of IgG up to 6 months.31 To date, 
only a few studies have quantified virus- specific antibodies in 
prepandemic samples to establish cut- off values to discrim-
inate between positive and negative samples,7 12 32 which 
allows comparison of results between studies. We found a 
similar proportion of positive samples for both IgA (from 
72.9% in our study to 80.0%7 12) and IgM (72.9% in our 
study compared with 55.0% in the study reported by Peng 
et al32). Of the samples, 17.1% did not present virus- specific 
antibodies, which is in accordance with a previous study 
(Fox Iscience). Also, accumulating data report the lack of 
SARS- CoV-2 IgG in serum after previous infection in some 
individuals; in fact, in a cohort study (n=2547),33 6.3% were 
reported to be IgG seronegative.
In this study, we also assessed the presence of antibodies 
against other non- structural viral proteins, specifically the viral 
cysteine- like protease, also known as 3CLPro or main viral 
protease (MPro).18 Our data showed the presence of anti- MPro 
IgA and IgG antibodies in milk samples from the COVID-19 
group compared with prepandemic samples, although the sensi-
tivity was lower than when using the RBD antigen for detection 
of virus- specific antibodies. MPro is a viral antigen not exposed 
on the viral particle like the spike protein; however, strong and 
similar reactivities were found for both MPro and RBD, and the 
nucleocapsid protein in serum and saliva samples.18 Our study 
is the first to use MPro for detection of SARS- CoV-2 antibodies 
in breast milk, and the reactivities to the different viral antigens, 
also in function of isotype, have been previously reported in 
breast milk.7 34
Our results are in agreement with previous data showing 
higher levels of antibodies against SARS- CoV-2 in milk from 
infected/recovered mothers compared with samples from 
women before the pandemic.30 35 However, prepandemic 
samples showed some reactivity to SARS- CoV-2, particularly 
in RBD- reactive IgA, which may be explained by cross- reaction 
with other seasonal coronavirus (HCoV) in breast milk samples 
before 2020, as previously reported.36 Women with COVID-19 
symptoms showed slightly higher virus- specific IgA levels in milk 
compared with women with asymptomatic infection, although 
differences were not significant. Moreover, no differences in 
IgM or IgG levels were found, possibly due to minor COVID-19 
symptoms (pain, headache, etc) in this data set. Despite these 
observations, further analyses including a bigger sample size and 
different symptoms as well as severe COVID-19- infected donors 
are warranted.
In summary, our study demonstrates (1) the absence of 
SARS- CoV-2 RNA in breast milk from women with COVID-19 
and (2) the high intervariability and intravariability in the 
SARS- CoV-2 antibody response. Women with COVID-19 exhib-
ited IgA, IgG and IgM antibodies in breast milk not only against 
structural proteins like RBD but also against non- structural 
proteins like MPro. The presence of Igs suggests that breast milk 
might have a protective effect in newborns. Interestingly, posi-
tive associations between total IgA and specific antibodies (IgA, 
IgG and IgM) were observed, although their persistence and 
stability differed between mothers and antibody type. Our study 
endorses the safety of breast feeding during the pandemic and 
highlights the potential relevance of virus- specific SARS- CoV-2 
antibodies providing passive immunity to breastfeeding infants, 
protecting them against COVID-19. Our study supports official 
recommendations stating the safety of breast feeding during the 
COVID-19 pandemic, indicating that breast feeding should be a 
priority with potential benefit for both mothers and neonates.
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Text S1. Extended Material and Methods 
Study population 
A control group of women not exposed to SARS-CoV-2 and from prepandemic time was 
included. Those women were randomly selected from the MAMI birth cohort in Spain [1] 
(ClinicalTrials.gov Identifier: NCT03552939). This protocol was approved by the Ethical 
Committee of the Hospital Clínico Universitario of Valencia (Ref. 2015/0024) and by the local 
Ethical Committee of Atención Primaria-Generalitat Valenciana (CEIC-APCV). 
 
Human milk collection and processing 
Breast milk collection was performed following a standardized protocol described elsewhere [2]. 
In brief, breast skin was cleaned with water and soap and the first drops were discarded. Then, 
milk was collected either by use of a sterile pump or manually extracted. Samples were collected 
in sterile bottles to normalize collection among participants. Morning collection was 
recommendable. Finally, breast milk samples were immediately stored at −20 °C in deep freezers 
and sent to the hospital to be stored at -80°C until further analysis.  
Whole milk was used for SARS-CoV-2 RNA detection. Whey milk samples were used for antibody 
determination and were prepared as follows: samples were thawed and centrifuged at 14,000 
rpm at 4 °C for 10 min to remove fat and the resulting supernatant was transferred into new 
tubes. Centrifugation was repeated twice to ensure removal of all cells and fat. Skimmed 
acellular milk was then aliquoted and frozen at -80 °C until further use. Pre-pandemic control 
milk samples were stored at -80°C before processing exactly as described for COVID-19 milk 
samples. 
 
Validation of SARS-CoV-2 RNA extraction, detection, and quantification in breast milk samples 
A manual column-based commercial kit (referred as MN) and an automated assisted method 
based on magnetic beads (referred as Max) were adapted following previous recommendations 
[3] and compared to assess their sensitivity for detecting viral particles in breast milk samples. 
Main modifications of providers’ official protocols included: 150 μL of whole breast milk were 
treated with Plant RNA Isolation Aid (Ambion, USA) prior to extraction with MN (Nucleospin RNA 
virus Kit, Macherey-Nagel GmbH & Co., Germany), while 300 μL of whole breast milk were used 
for nucleic acid isolation with Max (Maxwell® RSC Instrument coupled with Maxwell RSC Pure 
Food GMO and authentication kit, Promega, Spain). RNA was finally eluted in 100 μL nuclease-
free water in both extraction protocols.  
Initially, to characterize the viral recovery of both methods, porcine epidemic diarrhoea virus 
(PEDV) strain CV777 (an enveloped virus member of the Coronaviridae family and surrogate for 
SARS-CoV-2), and also, mengovirus (MgV) vMC0 (CECT 100000, non-enveloped member of the 
Picornaviridae designated in the ISO 15216-1:2017 standard method as process control) were 
spiked in phosphate buffer solution (PBS) and in breast milk. Detection ratios and limits of 
detection (LoD95% and LoD50%) were also characterized for both extraction methods by spiking 
serial dilutions of PEDV.  
Finally, serially diluted viral suspensions of gamma irradiated SARS-CoV-2 (Bei Resources; NR-
52287), and human coronavirus (HCoV) 229E (ATCC-VR740) were used to further define the 
analytical performances of Max extraction. Detection limits were calculated using the PODLOD 
calculation program v.9 according to [4]. 
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Viral RNA detection was performed by reverse transcription polymerase chain reactions (RT-
qPCR) using One Step PrimeScript™ RT-PCR Kit (Perfect Real Time) (Takara Bio, USA), targeting 
the N1 region of the nucleocapsid gene for SARS-CoV-2 [5], the membrane gene for HCoV 229-
E [6] and PEDV [7], and the region from 110 to 209 nucleotides for MgV [8]. The human RNase 
P gene [5] was used as quality control parameter for extraction. Reaction mixes, thermal cycling 
conditions, sequences for primers and probes, and standard quantification curves are detailed 
elsewhere [3,7]. Those for HCoV 229-E detection are included as supplementary material (Figure 
S1). Genome copies (gc) were calculated by using standard curves of 10-fold serial dilutions of 
SARS-CoV-2 genomic RNA (ATCC VR-1986D) or HCoV 229-E, PEDV and MgV suspensions in 
quintuplicates. 
All RT-qPCR assays were performed in duplicate on a LightCycler 480 instrument (Roche 
Diagnostics, Germany). Positive (genomic RNA), negative (nuclease-free water), and inhibition 
(either 10-fold diluted RNA or RP gene) controls were included in each assay.  
 
Breast milk SARS-CoV-2-specific antibody detection  
Levels of antibodies directed to structural proteins like the RBD of the SARS-CoV-2 spike protein 
and to non-structural viral proteins like the cysteine-like protease, also known as the main 
protease (Mpro) or 3CLpro, were analyzed.  
RBD-specific antibodies were determined using a previously published and validated ELISA 
protocol for use in human plasma and serum samples [9,10], modified for its use in human milk 
samples. RBD protein was produced under HHSN272201400008C and obtained through BEI 
Resources, NIAID, NIH: Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal 
Histidine Tag, Recombinant from HEK293T Cells, NR-52946. Briefly, 96-well ELISA immunoplates 
(Costar) were coated with RBD protein at 2 µg/mL and incubated at 4 °C overnight. Coated plates 
were blocked in 3 % (w/v) milk powder in PBS containing 0.1 % Tween 20 (PBS-T) for 1 h. Then, 
4-fold dilution of samples in 1 % (w/v) milk powder in PBS-T were added, incubated for 2 h at 
room temperature and washed with PBS-T before addition of horseradish peroxidase-
conjugated secondary antibodies. For detection of the different antibody isotypes, anti-human 
IgA (α-chain-specific) HRP antibody (Thermo-Fisher Scientific; A18781; 1:6.000), anti-human IgM 
(μ-chain-specific) HRP antibody (Sigma-Aldrich; A0420; 1:4.000), and anti-human IgG (Fc 
specific) HRP antibody (Sigma-Aldrich; A0170; 1:4.000) were used and incubated for 1 h in 1 % 
(w/v) milk powder in PBS-T. Bound antigen-specific antibodies were detected with 100 μL 
3,3′,5,5′-Tetramethylbenzidine (TMB) and reactions were stopped with 50 μL of 2M sulfuric acid. 
Absorbance at 450 nm was read in a ClarioStar (BMG Labtech) microplate reader using the path 
length correction mode. For detection of MPro-reactive antibodies, a commercial ELISA Kit 
(ImmunoStep, Salamanca, Spain) was used. Samples were incubated 1:4 diluted, and remaining 
steps of the protocol were performed according to manufacturer´s instructions. For ELISA 
studies, milk samples were considered positive when OD values from undiluted samples 
exceeded the positive cut-off values for each assay and isotype calculated from prepandemic 
control samples and defined as the mean + two standard deviations (SD). Values from dilution 
curves were used for determining the area under the curve (AUC) to get a better quantitative 
impression between COVID-19 and control group. Endpoint titers were calculated from log-
transformed titration curves using 4-parameter non-linear regression function in GraphPad 
Prism 8.0 and the positive cut-off values obtained from the prepandemic control group for each 
antigen and isotype.  
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Breast milk Total IgA quantification 
Total IgA, including secretory IgA (sIgA), was measured in whey milk using a sandwich ELISA 
quantitation kit from Bethyl Laboratories (Montgomery, TX) following manufacturer’s 
instructions as previously detailed [11]. Briefly, an anti-human IgA antibody pre-adsorbed to the 
plate allowed to capture the IgA, which was later detected by the addition of a biotinylated 
detection antibody and streptavidin-conjugated horseradish peroxidase that catalyzed the 
colorimetric reaction with the chromogenic substrate TMB. All whey milk samples were analyzed 
at a 1:8,000 dilution rate. Data were expressed as mg/L of milk. Duplicate determinations were 
performed on each plate. 
 
Statistical analysis 
Statistical analysis was performed in GraphPad Prism 8.0. After Shapiro-Wilk normality test, non-
parametric t-test (Mann-Whitney) was used to detect significant differences between groups 
and Spearman correlation analysis to assess correlations between variables. 
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Text S2: Extended Results 
 
Study population characteristics 
Among the 60 mothers, 52 were diagnosed with a SARS-CoV-2 PCR test in nasopharyngeal swabs 
while 8 mothers were seropositive (IgG positive). Most PCR tests (38/52, 73.1%) were performed 
as part of routine surveillance before labor. Table S1 specifies when SARS-CoV-2 was diagnosed 
either by PCR or by serology.   
 
Validation of SARS-CoV-2 RNA extraction and detection methods in breast milk 
To optimize SARS-CoV-2 viral RNA detection in breast milk samples, an initial analytical 
comparison aimed to determine the recovery of PEDV and MgV from spiked pre-pandemic 
breast milk samples using either a manual (MN) or an automated (Max) extraction method. 
Compared to spiked PBS, PEDV and MgV were recovered at 30 % (27-33 %) and 132 % (94-188 
%) when extracted from whole milk samples with MN, respectively. Conversely, better 
recoveries (˃100 %) were observed for both viruses extracted by Max. No significant inhibitions 
due the milk matrix were observed as depicted by the cycle threshold (Ct) values of 10-fold 
diluted RNA or RP gene reactions. 
By spiking PEDV serial dilutions in milk samples, we further defined the detection ratios and 
limits of detection (LoD95% and LoD50%), which are shown in Table S2. Results demonstrated 
similar sensibility of both extraction methods being 10 and 13 PEDV gc/100μL the limit of 
detection with 95 % confidence for MN and Max, respectively. These results suggest comparable 












BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Arch Dis Child Fetal Neonatal Ed




Table S1: Type of COVID-19 diagnosis (PCR/serology) and average time to sample collection 
COVID-19 diagnosis: n=60 
Positive nasopharyngeal PCR confirmation n=52 
 confirmation 48 h before delivery 38  
 confirmation 48 h after delivery 2 
 confirmation > 48 h before delivery 9 
 confirmation > 48 h after delivery 3 
Positive serology confirmation n=8 
 confirmation 48 h before/after delivery 3 
 confirmation > 48 h before delivery 1 
 confirmation > 48 h after delivery 4 
COVID-19 symptomatology  
Symptomatic prior or at enrollment  22 
Average time from COVID-19 diagnosis to breast milk sample collection 
Days post-PCR confirmation:   median 
                                                      minimum and maximum 
                                                      25th and 75th percentile 
15.0  
1 - 206 
6.0 – 29.8 
    Days post-serology confirmation:   median 
                                                              minimum and maximum 
                                                              25th and 75th percentile 
15.5 
1 - 226 
 (2.0 – 40.5) 
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Table S2. Concentrations, detection ratios, and limits of detection (LoD95% and LoD50%) 
characterizing the analytical performances of a manual commercial kit (MN) and an 
automated assisted method (Max) to extract porcine epidemic diarrhoea virus (PEDV) spiked 
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Supplementary Material
Primers and probe, reaction mix, thermal cycling conditions and calibration curve used to detect 
and quantify HCoV 229-E. 
Reaction mix (10 µL) consisted of 5·00 µL 2X One Step RT-PCR Buffer III, 0·20 µL PrimeScript RT 
enzyme Mix II, 0·20 µL ROX, 0·20 mL TaKaRa Ex Taq HS, 0·30 µL 229E-F and 229E-R primers 
(10mM), 0·15 µL 229E-P probe (10mM). The cycling parameters were as RT at 48 °C for 30 min, 
preheating at 95 °C for 10 min and 45 cycles of amplification at 95 °C for 15 s, and 60 °C for 1 
min.
Figure S1. Standard curve generated to quantify HCoV 229-E performed with 10-fold 
dilutions (100-107 gc/reaction) of genomic RNA.
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Figure S4: Breast milk from COVID-19 infected and/or recovered mothers show
significantly higher antibody binding to the RBD antigen of SARS-CoV-2 than
prepandemic controls and are detectable in 82.9 % of samples. AUC were calculated
from titration curves for RBD-reactive (a) IgA, (b) IgM, and (c) IgG in order to get a better
graphical impression. Asterisks show statistically significant differences between groups
(***p < 0·0001) using the Mann–Whitney test (unpaired nonparametric test). (d)
Proportion of human milk donors who had positive RBD-reactive Igs in at least one milk
recollection point, and negative samples (e) Proportion of RBD-reactive positive and
negative human milk samples subdivided according to different isotypes.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s)Arch Dis Child Fetal Neonatal Ed
 doi: 10.1136/archdischild-2021-322463–5.:10 2021;Arch Dis Child Fetal Neonatal Ed, et al. Bäuerl C
Figure S5: Samples from infected milk donors show significantly higher binding to SARS-
CoV-2 antigens RBD and Mpro compared to prepandemic control. Grouped OD values of
1:4 diluted samples of RBD- (a) and MPro- (b) reactive IgA, and RBD- (c) and MPro- (d)
reactive IgG, respectively. Asterisks show statistically significant differences between
groups (***p<0·0001, *p<0·05) using the Mann–Whitney test (unpaired nonparametric
test).
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Figure S6: Graph of positive rates of RBD-specific IgA, IgM and IgG versus days after
positive PCR diagnosis.
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Figure S9: Total IgA concentration and virus specific antibody response. 
(a) Spearmans’ correlation analysis of total IgA concentration and virus specific 
IgA response expressed as AUC. (b) Total IgA in COVID-19 infected and recovered 
and prepandemic control samples. Mann–Whitney test (unpaired nonparametric 
test) was used to assess for statistical significance.
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Text S1. Extended Material and Methods 
Study population 
A control group of women not exposed to SARS-CoV-2 and from prepandemic time was 
included. Those women were randomly selected from the MAMI birth cohort in Spain [1] 
(ClinicalTrials.gov Identifier: NCT03552939). This protocol was approved by the Ethical 
Committee of the Hospital Clínico Universitario of Valencia (Ref. 2015/0024) and by the local 
Ethical Committee of Atención Primaria-Generalitat Valenciana (CEIC-APCV). 
 
Human milk collection and processing 
Breast milk collection was performed following a standardized protocol described elsewhere [2]. 
In brief, breast skin was cleaned with water and soap and the first drops were discarded. Then, 
milk was collected either by use of a sterile pump or manually extracted. Samples were collected 
in sterile bottles to normalize collection among participants. Morning collection was 
recommendable. Finally, breast milk samples were immediately stored at −20 °C in deep freezers 
and sent to the hospital to be stored at -80°C until further analysis.  
Whole milk was used for SARS-CoV-2 RNA detection. Whey milk samples were used for antibody 
determination and were prepared as follows: samples were thawed and centrifuged at 14,000 
rpm at 4 °C for 10 min to remove fat and the resulting supernatant was transferred into new 
tubes. Centrifugation was repeated twice to ensure removal of all cells and fat. Skimmed 
acellular milk was then aliquoted and frozen at -80 °C until further use. Pre-pandemic control 
milk samples were stored at -80°C before processing exactly as described for COVID-19 milk 
samples. 
 
Validation of SARS-CoV-2 RNA extraction, detection, and quantification in breast milk samples 
A manual column-based commercial kit (referred as MN) and an automated assisted method 
based on magnetic beads (referred as Max) were adapted following previous recommendations 
[3] and compared to assess their sensitivity for detecting viral particles in breast milk samples. 
Main modifications of providers’ official protocols included: 150 μL of whole breast milk were 
treated with Plant RNA Isolation Aid (Ambion, USA) prior to extraction with MN (Nucleospin RNA 
virus Kit, Macherey-Nagel GmbH & Co., Germany), while 300 μL of whole breast milk were used 
for nucleic acid isolation with Max (Maxwell® RSC Instrument coupled with Maxwell RSC Pure 
Food GMO and authentication kit, Promega, Spain). RNA was finally eluted in 100 μL nuclease-
free water in both extraction protocols.  
Initially, to characterize the viral recovery of both methods, porcine epidemic diarrhoea virus 
(PEDV) strain CV777 (an enveloped virus member of the Coronaviridae family and surrogate for 
SARS-CoV-2), and also, mengovirus (MgV) vMC0 (CECT 100000, non-enveloped member of the 
Picornaviridae designated in the ISO 15216-1:2017 standard method as process control) were 
spiked in phosphate buffer solution (PBS) and in breast milk. Detection ratios and limits of 
detection (LoD95% and LoD50%) were also characterized for both extraction methods by spiking 
serial dilutions of PEDV.  
Finally, serially diluted viral suspensions of gamma irradiated SARS-CoV-2 (Bei Resources; NR-
52287), and human coronavirus (HCoV) 229E (ATCC-VR740) were used to further define the 
analytical performances of Max extraction. Detection limits were calculated using the PODLOD 
calculation program v.9 according to [4]. 
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Viral RNA detection was performed by reverse transcription polymerase chain reactions (RT-
qPCR) using One Step PrimeScript™ RT-PCR Kit (Perfect Real Time) (Takara Bio, USA), targeting 
the N1 region of the nucleocapsid gene for SARS-CoV-2 [5], the membrane gene for HCoV 229-
E [6] and PEDV [7], and the region from 110 to 209 nucleotides for MgV [8]. The human RNase 
P gene [5] was used as quality control parameter for extraction. Reaction mixes, thermal cycling 
conditions, sequences for primers and probes, and standard quantification curves are detailed 
elsewhere [3,7]. Those for HCoV 229-E detection are included as supplementary material (Figure 
S1). Genome copies (gc) were calculated by using standard curves of 10-fold serial dilutions of 
SARS-CoV-2 genomic RNA (ATCC VR-1986D) or HCoV 229-E, PEDV and MgV suspensions in 
quintuplicates. 
All RT-qPCR assays were performed in duplicate on a LightCycler 480 instrument (Roche 
Diagnostics, Germany). Positive (genomic RNA), negative (nuclease-free water), and inhibition 
(either 10-fold diluted RNA or RP gene) controls were included in each assay.  
 
Breast milk SARS-CoV-2-specific antibody detection  
Levels of antibodies directed to structural proteins like the RBD of the SARS-CoV-2 spike protein 
and to non-structural viral proteins like the cysteine-like protease, also known as the main 
protease (Mpro) or 3CLpro, were analyzed.  
RBD-specific antibodies were determined using a previously published and validated ELISA 
protocol for use in human plasma and serum samples [9,10], modified for its use in human milk 
samples. RBD protein was produced under HHSN272201400008C and obtained through BEI 
Resources, NIAID, NIH: Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal 
Histidine Tag, Recombinant from HEK293T Cells, NR-52946. Briefly, 96-well ELISA immunoplates 
(Costar) were coated with RBD protein at 2 µg/mL and incubated at 4 °C overnight. Coated plates 
were blocked in 3 % (w/v) milk powder in PBS containing 0.1 % Tween 20 (PBS-T) for 1 h. Then, 
4-fold dilution of samples in 1 % (w/v) milk powder in PBS-T were added, incubated for 2 h at 
room temperature and washed with PBS-T before addition of horseradish peroxidase-
conjugated secondary antibodies. For detection of the different antibody isotypes, anti-human 
IgA (α-chain-specific) HRP antibody (Thermo-Fisher Scientific; A18781; 1:6.000), anti-human IgM 
(μ-chain-specific) HRP antibody (Sigma-Aldrich; A0420; 1:4.000), and anti-human IgG (Fc 
specific) HRP antibody (Sigma-Aldrich; A0170; 1:4.000) were used and incubated for 1 h in 1 % 
(w/v) milk powder in PBS-T. Bound antigen-specific antibodies were detected with 100 μL 
3,3′,5,5′-Tetramethylbenzidine (TMB) and reactions were stopped with 50 μL of 2M sulfuric acid. 
Absorbance at 450 nm was read in a ClarioStar (BMG Labtech) microplate reader using the path 
length correction mode. For detection of MPro-reactive antibodies, a commercial ELISA Kit 
(ImmunoStep, Salamanca, Spain) was used. Samples were incubated 1:4 diluted, and remaining 
steps of the protocol were performed according to manufacturer´s instructions. For ELISA 
studies, milk samples were considered positive when OD values from undiluted samples 
exceeded the positive cut-off values for each assay and isotype calculated from prepandemic 
control samples and defined as the mean + two standard deviations (SD). Values from dilution 
curves were used for determining the area under the curve (AUC) to get a better quantitative 
impression between COVID-19 and control group. Endpoint titers were calculated from log-
transformed titration curves using 4-parameter non-linear regression function in GraphPad 
Prism 8.0 and the positive cut-off values obtained from the prepandemic control group for each 
antigen and isotype.  
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Breast milk Total IgA quantification 
Total IgA, including secretory IgA (sIgA), was measured in whey milk using a sandwich ELISA 
quantitation kit from Bethyl Laboratories (Montgomery, TX) following manufacturer’s 
instructions as previously detailed [11]. Briefly, an anti-human IgA antibody pre-adsorbed to the 
plate allowed to capture the IgA, which was later detected by the addition of a biotinylated 
detection antibody and streptavidin-conjugated horseradish peroxidase that catalyzed the 
colorimetric reaction with the chromogenic substrate TMB. All whey milk samples were analyzed 
at a 1:8,000 dilution rate. Data were expressed as mg/L of milk. Duplicate determinations were 
performed on each plate. 
 
Statistical analysis 
Statistical analysis was performed in GraphPad Prism 8.0. After Shapiro-Wilk normality test, non-
parametric t-test (Mann-Whitney) was used to detect significant differences between groups 
and Spearman correlation analysis to assess correlations between variables. 
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Text S2: Extended Results 
 
Study population characteristics 
Among the 60 mothers, 52 were diagnosed with a SARS-CoV-2 PCR test in nasopharyngeal swabs 
while 8 mothers were seropositive (IgG positive). Most PCR tests (38/52, 73.1%) were performed 
as part of routine surveillance before labor. Table S1 specifies when SARS-CoV-2 was diagnosed 
either by PCR or by serology.   
 
Validation of SARS-CoV-2 RNA extraction and detection methods in breast milk 
To optimize SARS-CoV-2 viral RNA detection in breast milk samples, an initial analytical 
comparison aimed to determine the recovery of PEDV and MgV from spiked pre-pandemic 
breast milk samples using either a manual (MN) or an automated (Max) extraction method. 
Compared to spiked PBS, PEDV and MgV were recovered at 30 % (27-33 %) and 132 % (94-188 
%) when extracted from whole milk samples with MN, respectively. Conversely, better 
recoveries (˃100 %) were observed for both viruses extracted by Max. No significant inhibitions 
due the milk matrix were observed as depicted by the cycle threshold (Ct) values of 10-fold 
diluted RNA or RP gene reactions. 
By spiking PEDV serial dilutions in milk samples, we further defined the detection ratios and 
limits of detection (LoD95% and LoD50%), which are shown in Table S2. Results demonstrated 
similar sensibility of both extraction methods being 10 and 13 PEDV gc/100μL the limit of 
detection with 95 % confidence for MN and Max, respectively. These results suggest comparable 
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Table S1: Type of COVID-19 diagnosis (PCR/serology) and average time to sample collection 
COVID-19 diagnosis: n=60 
Positive nasopharyngeal PCR confirmation n=52 
 confirmation 48 h before delivery 38  
 confirmation 48 h after delivery 2 
 confirmation > 48 h before delivery 9 
 confirmation > 48 h after delivery 3 
Positive serology confirmation n=8 
 confirmation 48 h before/after delivery 3 
 confirmation > 48 h before delivery 1 
 confirmation > 48 h after delivery 4 
COVID-19 symptomatology  
Symptomatic prior or at enrollment  22 
Average time from COVID-19 diagnosis to breast milk sample collection 
Days post-PCR confirmation:   median 
                                                      minimum and maximum 
                                                      25th and 75th percentile 
15.0  
1 - 206 
6.0 – 29.8 
    Days post-serology confirmation:   median 
                                                              minimum and maximum 
                                                              25th and 75th percentile 
15.5 
1 - 226 
 (2.0 – 40.5) 
 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Arch Dis Child Fetal Neonatal Ed
 doi: 10.1136/archdischild-2021-322463–6.:10 2021;Arch Dis Child Fetal Neonatal Ed, et al. Bäuerl C
 
 
Table S2. Concentrations, detection ratios, and limits of detection (LoD95% and LoD50%) 
characterizing the analytical performances of a manual commercial kit (MN) and an 
automated assisted method (Max) to extract porcine epidemic diarrhoea virus (PEDV) spiked 
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Supplementary Material
Primers and probe, reaction mix, thermal cycling conditions and calibration curve used to detect 
and quantify HCoV 229-E. 
Reaction mix (10 µL) consisted of 5·00 µL 2X One Step RT-PCR Buffer III, 0·20 µL PrimeScript RT 
enzyme Mix II, 0·20 µL ROX, 0·20 mL TaKaRa Ex Taq HS, 0·30 µL 229E-F and 229E-R primers 
(10mM), 0·15 µL 229E-P probe (10mM). The cycling parameters were as RT at 48 °C for 30 min, 
preheating at 95 °C for 10 min and 45 cycles of amplification at 95 °C for 15 s, and 60 °C for 1 
min.
Figure S1. Standard curve generated to quantify HCoV 229-E performed with 10-fold 
dilutions (100-107 gc/reaction) of genomic RNA.
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Figure S4: Breast milk from COVID-19 infected and/or recovered mothers show
significantly higher antibody binding to the RBD antigen of SARS-CoV-2 than
prepandemic controls and are detectable in 82.9 % of samples. AUC were calculated
from titration curves for RBD-reactive (a) IgA, (b) IgM, and (c) IgG in order to get a better
graphical impression. Asterisks show statistically significant differences between groups
(***p < 0·0001) using the Mann–Whitney test (unpaired nonparametric test). (d)
Proportion of human milk donors who had positive RBD-reactive Igs in at least one milk
recollection point, and negative samples (e) Proportion of RBD-reactive positive and
negative human milk samples subdivided according to different isotypes.
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Figure S5: Samples from infected milk donors show significantly higher binding to SARS-
CoV-2 antigens RBD and Mpro compared to prepandemic control. Grouped OD values of
1:4 diluted samples of RBD- (a) and MPro- (b) reactive IgA, and RBD- (c) and MPro- (d)
reactive IgG, respectively. Asterisks show statistically significant differences between
groups (***p<0·0001, *p<0·05) using the Mann–Whitney test (unpaired nonparametric
test).
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Figure S6: Graph of positive rates of RBD-specific IgA, IgM and IgG versus days after
positive PCR diagnosis.
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Figure S9: Total IgA concentration and virus specific antibody response. 
(a) Spearmans’ correlation analysis of total IgA concentration and virus specific 
IgA response expressed as AUC. (b) Total IgA in COVID-19 infected and recovered 
and prepandemic control samples. Mann–Whitney test (unpaired nonparametric 
test) was used to assess for statistical significance.
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